Global Market Size, Forecast, and Trend Highlights Over 2025-2037
HIV Drugs Market size was valued at USD 36.72 billion in 2024 and is likely to cross USD 79.29 billion by 2037, expanding at more than 6.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of HIV drugs is estimated at USD 38.62 billion.
The growth of the HIV drugs market can be attributed to prevailing cases of acquired immune deficiency syndrome (AIDS). AIDS is caused by the transmission of a virus named human immunodeficiency virus (HIV). The data released by World Health Organisation states that in 2020, there were 1.5 million people who acquired HIV, and 680,000 people died from HIV-related causes. WHO also claims that in 2020 there were 37.7 million people who are living with AIDS. On the back of emerging cases of AIDS, the market is expected to grow during the forecast period. Furthermore, the governments are raising expenditure for the prevention and treatment of the disease. According to a report released by Joint United Nations Programme on HIV/AIDS (UNAIDS), the availability of international and domestic resources for the prevention and treatment of AIDS reached USD 21.5 million by the end of 2020. On account of the availability of a humongous budget for the treatment of AIDS, the market is projected to grow during the forecast period. Furthermore, the pro-active participation from all over the world to eliminate AIDS is remarkable. The World Health Organization promulgates 1st December as World AIDS Day to spread awareness about the prevention and treatment of the disease. The HIV drugs market is estimated to witness significant growth during the forecast period on account of the rising awareness amongst the people.
HIV Drugs Sector: Growth Drivers and Challenges
Growth Drivers
-
Surging Cases of Cancer Worldwide
- Rising Initiatives by the Governments
Challenges
-
Lack of Awareness Regarding the Treatment
HIV Drugs Segmentation
The HIV drugs market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, the hospital pharmacies sub-segment is anticipated to hold the largest share in the market during the forecast period on account of the growing number of HIV patients. A large number of HIV patients get admitted to hospitals is estimated to boost the market growth.
Our in-depth analysis of the global market includes the following segments:
Medication Class |
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportHIV Drugs Industry - Regional Synopsis
Regionally, the HIV drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America industry is anticipated to account for largest revenue share by 2037, on the back of presence of an ultra-modern healthcare system. Furthermore, countries such as the USA are making people aware of the prevention and treatment of AIDS. The data released by the American Psychological Association states that 10th April is celebrated as National Youth HIV and AIDS Awareness Day. This event is celebrated to raise awareness amongst youth regarding the treatment of AIDS.
Furthermore, the market is expected to grow during the forecast period in the Asia Pacific region owing to a large number of patients in the region. According to the data released by UNAIDS in 2020, there were 5.8 million people living with HIV in the APAC region. On the back of the escalating number of HIV patients in the region, the HIV drugs market is projected to grow during the forecast period. Furthermore, the governments in the region are allotting a plethora of budgets for the prevention and treatment of HIV.
![HIV-Drugs-Market-Share](https://dq300iingq64j.cloudfront.net/s3-uploads/report-img/HIV-Drugs-Market-Share.jpg)
Companies Dominating the HIV Drugs Landscape
- Merck & Co., Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Boehringer Ingelheim International GmbH
- Gilead Sciences, Inc.
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche Ltd.
- Cipla Inc.
- Teva Pharmaceuticals Industries Ltd.
- Janssen Global Services, LLC
- Mylan N.V.
- AbbVie Inc.
In the News
-
March 23, 2020: Gilead affirms that its supply chain is resilient even in the pandemic and does not see shortages of HIV treatment or prevention medicines in the future.
Author Credits: Radhika Pawar
- Report ID: 162
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT